Elevated PSA as Differential Diagnostic Error-Source in Prostate Cancer with Consequences in Medical Law

Bichler, K.-H.; Naber, Kurt G.

doi:10.1007/978-3-319-25175-2_14

Search citation statements

Order By: Relevance

Paper Sections

Select...

Psa1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 29 This excludes rises due to other nonmalignant conditions such as PSA bounce, 30 receptive anal intercourse, 31 , 32 prostatic trauma, 33 prostatitis, 34 or confirmed laboratory errors. 35 Moreover, time of PSA failure was determined at PSA result time and not backdated as in the ASTRO definition. Investigators may continue to use the ASTRO definition of PSA failure for EBRT or brachytherapy, when no hormonal therapy was provided to the patient in addition.…”

Section: Psamentioning

confidence: 99%

Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer

Nasser

Klein

Agbarya

2021

Advances in Radiation Oncology

View full text Add to dashboard Cite

The main treatment modalities for localized prostate cancer are surgery and radiation. Surgery removes the whole prostate gland, whereas with radiation therapy the irradiated prostate remains within the patient's body. Biomarkers specific to the prostate gland should become undetectable after surgery, but this is not the case when radiation therapy is used, as residual prostate cells may still be metabolically active. Here, we review the role of tumor markers of toxicity and response to radiation therapy in patients with prostate cancer, including prostate specific antigen, human kallikrein 2, osteopontin, prostate cancer associated 3, citrulline, and others.

show abstract